Horizon Discovery powers up gene editing proposition for global clients
Horizon Discovery Group has enthused scientists worldwide by powering up its gene editing technology offering.
Already a global leader in the application of gene editing and gene modulation technologies, Cambridge-headquartered Horizon has added predesigned synthetic single guide RNA (sgRNA) to its product range.
The sgRNAs, available individually or as library collections, expand the company’s Edit-R gene engineering platform which provides a convenient and accessible approach to successful CRISPR gene editing.
Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts in even complex, difficult-to-edit cell types and experimental models.
The synthetic sgRNAs have been designed using Horizon’s proprietary algorithm to maximise the likelihood of functionally knocking out the gene(s) of interest while minimising off-target effects.
These predesigned synthetic sgRNAs, when paired with Cas9 mRNA or Cas9 protein, allow researchers to perform DNA-free gene editing in a new one-part format thereby streamlining their gene editing workflows, without the potential for nuclease or guide integration into the cell’s genome.
They can also be paired with expressed formats such as Cas9 integrated cell lines, which is ideal for high-throughput library screening.
The release of predesigned sgRNA expands Horizon’s Edit-R platform. Library collections of sgRNAs, from common gene families up to the entire genome, are available to support large-scale screening applications.
The company will continue to provide its CRISPR design tool, where customers can design custom guide RNA to edit a specific region within a DNA transcript or input their own guide RNA target sequence to generate ready-to-use sgRNA.